1Cademy - In a French open-label non-randomized clinical trial, more patients treated with hydroxychloroquine+azithromycin tested negative for COVID-19 by day 6 after inclusion in study compared to a control group

Learn Before

Findings in favor of treating COVID-19 infections with hydroxychloroquine (HCQ) + azithromycin (AZM)

Concept

In a French open-label non-randomized clinical trial, more patients treated with hydroxychloroquine+azithromycin tested negative for COVID-19 by day 6 after inclusion in study compared to a control group

by day 3 of the study, 5/6 patients treated with HCQ+AZM tested negative for COVID-19 compared to 1/16 control patients (untreated)
by day 6, 6/6 patients given HCQ+AZM tested negative compared to 2/16 control patients

Updated 2020-07-22

Contributors are:

Lisa Mayer

🏆 1

Who are from:

University of Michigan - Ann Arbor

🏆 1

References

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.

Learn Before

Related